Yunnan Watson Biotechnology

Walvax Biotechnology is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of human vaccines. Founded in 2001 and headquartered in Kunming, the company has achieved significant milestones, including the launch of the world's second 13-valent pneumococcal conjugate vaccine (PCV13) and China's first domestically developed 2-valent HPV vaccine. Walvax is a pioneer in mRNA technology within China, collaborating with partners like Abogen Biosciences to develop COVID-19 mRNA vaccines and other infectious disease candidates. The company operates large-scale GMP manufacturing facilities and maintains a robust pipeline targeting high-burden diseases such as shingles, influenza, and multi-valent HPV. Walvax is listed on the Shenzhen Stock Exchange and is increasingly focused on expanding its footprint in global public health markets.